Stocks
Merck's Explosive Growth: $1,000 Investment Surges 239% Over Decade
A $1,000 investment in Merck (MRK) ten years ago has grown by 239.48%, outperforming the S&P 500 over that period. However, this growth was concentrated in just one year, with shares rising by 95.25%.
Merck's flagship product, Keytruda, drove revenue growth, generating $8.4 billion in Q2 2026, up 4% from the same quarter in 2025. Despite its success, Merck trailed the S&P 500 for a decade before surging ahead.
The company's trailing P/E of 119x is distorted by acquisition charges, which pushed Q1 2026 EPS to -$1.28 and Q2 EPS to -$0.13. The forward P/E of 15x better reflects Merck's true earnings power.